These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37152010)

  • 1. Receptor-ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma.
    Mao S; Zeng L; Yang Y; Liu Z; Zhang L
    Front Oncol; 2023; 13():1170942. PubMed ID: 37152010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data.
    Jiang YQ; Wang ZX; Zhong M; Shen LJ; Han X; Zou X; Liu XY; Deng YN; Yang Y; Chen GH; Deng W; Huang JH
    Oncoimmunology; 2021 Apr; 10(1):1908010. PubMed ID: 33868792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.
    Huang J; Yuan L; Huang W; Liao L; Zhu X; Wang X; Li J; Liang W; Wu Y; Liu X; Yu D; Zheng Y; Guan J; Zhan Y; Liu L
    Front Immunol; 2022; 13():1064874. PubMed ID: 36505456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
    J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
    Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
    PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
    Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
    Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.
    Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R
    Front Immunol; 2022; 13():749241. PubMed ID: 35529878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m7G-related gene NUDT4 as a novel biomarker promoting cancer cell proliferation in lung adenocarcinoma.
    Liu Y; Jiang B; Lin C; Zhu W; Chen D; Sheng Y; Lou Z; Ji Z; Wu C; Wu M
    Front Oncol; 2022; 12():1055605. PubMed ID: 36761423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Lung Adenocarcinoma.
    Huang H; Zhu G; Shi R; Li Y; Zhang Z; Xu S; Chen C; Cao P; Pan Z; Zhang H; Liu M; Liu H; Chen J
    J Cancer; 2022; 13(8):2631-2643. PubMed ID: 35711827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma.
    Zheng Y; Tian H; Zhou Z; Xiao C; Liu H; Liu Y; Wang L; Fan T; Zheng B; Tan F; Xue Q; Gao G; Li C; He J
    Front Cell Dev Biol; 2021; 9():651406. PubMed ID: 33816503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
    Wang N; Zhu L; Xu X; Yu C; Huang X
    Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
    Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
    J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma.
    Zhou N; Tang Q; Yu H; Li T; Ren F; Zu L; Chen G; Chen J; Xu S
    Front Mol Biosci; 2022; 9():1034208. PubMed ID: 36438661
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
    Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
    Front Immunol; 2022; 13():960738. PubMed ID: 36032135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing.
    Zhang J; Liu X; Huang Z; Wu C; Zhang F; Han A; Stalin A; Lu S; Guo S; Huang J; Liu P; Shi R; Zhai Y; Chen M; Zhou W; Bai M; Wu J
    Comput Biol Med; 2023 Jan; 152():106460. PubMed ID: 36565482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.